Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
109 hedge funds and large institutions have $268M invested in Esperion Therapeutics in 2016 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 28 reducing their positions, and 19 closing their positions.
62% more call options, than puts
Call options by funds: $3.74M | Put options by funds: $2.31M
43% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 28
4% less funds holding
Funds holding: 113 → 109 (-4)
16% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 19
27% less capital invested
Capital invested by funds: $366M → $268M (-$97.4M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$9.76M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$2.98M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
+$2.97M |
| 4 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$2.23M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.3M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$4.98M |
| 4 |
Renaissance Technologies
New York
|
-$4.08M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$2.96M |
ESPR Hedge Fund Activity: Q1 2016 in Review
109 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2016, worth a combined $268M — down 27% from $366M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ESPR and 16 opened new positions — a net loss of 3 holders — while 28 trimmed existing stakes and 40 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $9.76M. The largest seller was State Street, cutting an estimated $13.3M.
- 109 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2016, down from 113 in Q4 2015.
- Funds reported $268M of Esperion Therapeutics stock for Q1 2016, down 27% quarter-over-quarter.
- 16 funds opened new Esperion Therapeutics positions in Q1 2016 and 19 closed out, a net change of -3 holders.
- The largest Esperion Therapeutics buyer in Q1 2016 was BVF Inc, an estimated $9.76M added.
- The largest Esperion Therapeutics seller in Q1 2016 was State Street, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2016.